Similarly, the SORAML trial randomized patients with FLT3 mutated AML to standard therapy with or without sorafenib (at a dose of 400 mg twice daily); for patients in CR1 the protocol added maintenance sorafenib or placebo (81). The gene discussed is FLT3; the disease is acute myeloid leukemia.